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Background
Omalizumab is a biologic molecule which is used on
severe allergic asthma patients. Omalizumab, which
shows effect by binding to free IgE molecule in circula-
tion, is reported to be effective in nonallergic asthma
patients in some case reports.
Methods
Case 1, a fifty one-year old woman who has been treated
for 11 years diagnosis of asthma, went to emergency ser-
vice four times last year in spite of taking high dose
inhaler corticosteroid. In her physical examination wide-
spread rhonchi was oscultated. FEV1: %76, total IgE:
897 IU/mL inhalant skin prick tests and mites spesific
IgE were negative. Visual Analog Score(VAS) was 2,
asthma symptom score (ASS) was determined as 6.
Omalizumab was started 450mg/month as diagnosis of
nonallergic asthma. One week after the first injection of
omalizumab, patient’s complaints got better. The patient
is taking omalizumab for ten months and VAS is 8, ASS
is 2, can use salbutamol if necessary.
Case 2, a sixty nine-year old woman patient has
hypertension, epilepsy, anxiety disorder as well as 12
years of asthma. She consulted the emergency countless
times and stayed in hospital twice last year. The patient
is still using high dose of inhaler corticosteroid and
using oral corticosteroid constantly. FEV1: %73, inhalant
skin prick tests were negative. Total IgE: 116 IU/mL
mite and mold spesific IgE were negative. At the beggin-
ning, the patient whose VAS 3, ASS 8, is taking 300 mg
of Omalizumab every month. The patient’s symptoms
got better after the second dose of treatment and the
VAS was 8, ASS was 3 in the 9th month of omalizumab.
The patient is still using one dose of budesonid/formo-
terol and the other disease is under control.
In both of the cases, there wasn’t any emergency con-
sult or hospitilization.
Results
The text does not involve results.
Conclusions
The clinical efficiency of omalizumab on normal-severe
allergic asthmas is showed by a lot of studies. GINA
(Global Initiative of Asthma) is said to be a treatment
choice for patients who are sensitive of perennial aller-
gens. Although IgE levels were high in both of our
cases, not only skin prick tests but also they were
patients whose perennial allergenic spesific IgE was
negative. Recently studies show that there is no differ-
ence in inflammatory cytokines releasing or expression
of high affinity Ig E receptor allergic or non-allergic
asthma. We know that effect of omalizumab is via free
IgE molecule in circulation. In this effect, role of atopy
is arguable.
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